, /PRNewswire/ -- In a significant stride towards preventing antimicrobial resistance, Smart Blood Analytics Swiss proudly announces the attainment of EU-MDR (European Medical Device Regulation) certification for their VIRUS vs. BACTERIA Clinical Decision Support Software. This innovative medical device sets a new benchmark in accurately distinguishing between viral and bacterial infections, thus aiding physicians in delivering targeted and effective treatment to patients.
Antimicrobial resistance (AMR) poses a significant threat to global public health and development, contributing to millions of deaths annually. Mainly driven by the misuse and overuse of antibiotics, AMR undermines the effectiveness of treatments for infectious diseases, putting modern medical advancements at risk and increasing healthcare costs substantially. The World Health Organization (WHO) emphasizes preventing infections, ensuring universal access to quality diagnosis and treatment, and promoting innovation in surveillance and research to address antimicrobial resistance in human health.
As the first Clinical Decision Support Software to receive EU-MDR certification in the field of infectious disease management, VIRUS vs. BACTERIA utilizes only 17 routine blood parameters, biological sex, and age to distinguish between viral and bacterial infections. The VIRUS vs.
BACTERIA model has also recently been showcased in an article published in Heliyon, highlighting its effectiveness and great accuracy ( )..
